Potential effects of omega-3 fatty acids on anemia and inflammatory markers in maintenance hemodialysis patients

DARU, Journal of Pharmaceutical Sciences

Volumn 22, Issue 1, 2014, Pages

  Gharekhani, Afshin ^a   Khatami, Mohammad Reza ^b   Dashti Khavidaki, Simin ^a,b   Razeghi, Effat ^b   Abdollahi, Alireza ^b   Hashemi Nazari, Seyed Saeed ^c   Mansournia, Mohammad Ali ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anemia; Hemodialysis; Inflammation; Omega 3 fatty acids

Indexed keywords

EID: 84894253673     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-22-11     Document Type: Article

References (47)

1. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Tessitore N, Girelli D, Campostrini N, Bedogna V, Solero GP, Castagna A, Melilli E, Mantovani W, Matteis GD, Olivieri O, et al. Nephrol Dial Transplant 2010 25 3996 4002 10.1093/ndt/gfq321 20538788
2. Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Swinkels DW, Wetzels JFM, Nephrol Dial Transplant 2008 23 2450 2453 10.1093/ndt/gfn267 18495744
3. Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: potential role of prohepcidin, hepcidin, and inflammation. Malyszko J, Malyszko JS, Mysliwiec M, Ren Fail 2009 31 544 548 10.1080/08860220903082606 19839848
4. Hepcidin in anemia and inflammation in chronic kidney disease. Malyszko J, Mysliwiec, Kidney Blood Press Res 2007 30 15 30 10.1159/000098522 17215586
5. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE, Kidney Int 1996 50 1694 1699 10.1038/ki.1996.487 8914038 (Pubitemid 26364277)
6. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Barany P, Divino Filho JC, Bergstrom J, Am J Kidney Dis 1997 29 565 568 10.1016/S0272-6386(97)90339-5 9100046 (Pubitemid 27155278)
7. Molecular control of iron transport. Ganz T, J Am Soc Nephrol 2007 18 394 400 10.1681/ASN.2006070802 17229910 (Pubitemid 46193304)
8. Hepcidin, a new iron regulatory peptide. Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S, Blood Cells Mol Dis 2002 29 327 335 10.1006/bcmd.2002.0573 12547223
9. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Putten KVD, Jie KE, Broek DVD, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, Braam B, Gaillard CA, Eur J Heart Fail 2010 12 943 950 10.1093/eurjhf/hfq099 20601671
10. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Zaritsky J, Young B, Gales B, Wang H, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB, Clin J Am Soc Nephrol 2010 5 1010 1014 10.2215/CJN.08161109 20299375
11. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip system. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I, Blood 2006 108 1381 1387 10.1182/blood-2005-10-4043 16621968 (Pubitemid 44232041)
12. Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Zaritsky J, Young B, Wang H, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB, Clin J Am Soc Nephrol 2009 4 1051 1056 10.2215/CJN.05931108 19406957
13. HEF mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients. Valenti L, Girelli D, Valenti GF, Castagna A, Como G, Campostrini N, Rametta R, Dongiovanni P, Messa P, Fargion S, Clin J Am Soc Nephrol 2009 4 1331 1337 10.2215/CJN.01370209 19541813
14. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Peters HPE, Laarakkers CMM, Swinkels DW, Wetzels JFM, Nephrol Dial Transplant 2010 25 848 853 10.1093/ndt/gfp546 19854845
15. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, Kobold U, Mayer G, Eur J Clin Invest 2009 39 883 890 10.1111/j.1365-2362.2009.02182.x 19563467
16. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Dallalio G, Law E, Means RT Jr, Blood 2006 107 2702 2704 10.1182/blood-2005-07-2854 16332970
17. Review of the effects of omega-3 supplementation in dialysis patients. Friedman A, Moe S, Clin J Am Soc Nephrol 2006 1 182 192 10.2215/CJN.00740805 17699207 (Pubitemid 43334212)
18. Fish consumption and omega-3 fatty acid status and determinants in long-term hemodialysis. Friedman AN, Moe SM, Perkins SM, Li Y, Watkins BA, Am J Kidney Dis 2006 47 1064 1071 10.1053/j.ajkd.2006.03.033 16731302 (Pubitemid 43767330)
19. Effect of n-3 fatty acids on nutritional status and inflammatory markers in haemodialysis patients. Perunicic-Pekovic GB, Rasic ZR, Pljesa SI, Sobajic SS, Djuricic I, Maletic R, Ristic-Medic DK, Nephrology 2007 12 331 336 10.1111/j.1440-1797.2007.00777.x 17635746 (Pubitemid 47075407)
20. Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients-a pilot study. Saifullah A, Watkins BA, Saha C, Li Y, Moe SM, Friedman AN, Nephrol Dial Transplant 2007 22 3561 3567 10.1093/ndt/gfm422 17623719 (Pubitemid 350212489)
21. Effects of n-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients. Rasic-Milutinovic Z, Perunicic G, Pljesa S, Gluvic Z, Sobajic S, Djuric I, Ristic D, Ren Fail 2007 29 321 329 10.1080/08860220601184092 17497447 (Pubitemid 46752347)
22. Short-term administration of omega-3 fatty acids in hemodialysis patients with balanced lipid metabolism. Fiedler R, Mall M, Wand C, Osten B, J Ren Nutr 2005 15 253 256 10.1053/j.jrn.2005.01.007 15827899
23. The effect of n-3 fatty acids on C-reactive protein levels in patients with chronic renal failure. Madsen T, Schmidt EB, Christensen JH, J Ren Nutr 2007 17 258 263 10.1053/j.jrn.2007.03.003 17586424 (Pubitemid 46936230)
24. Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients. Kooshki A, Taleban FA, Tabibi H, Hedayati M, Ren Fail 2011 33 892 898 10.3109/0886022X.2011.605536 21859401
25. Advancements in anemias related to chronic conditions. Guidi GC, Santonastaso CL, Clin Chem Lab Med 2010 48 1217 1226 20618092
26. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Levin A, Kidney Int Suppl 2002 80 35 38 11982810
27. Effect of n-3 fatty acids from fish oil on hemostasis, blood pressure, and lipid profile of dialysis patients. Donnelly SM, Ali MA, Churchill DN, J Am Soc Nephrol 1992 2 1634 1639 1610984
28. An anti-inflammatory and antioxidant nutritional supplement for hypoalbuminemic hemodialysis patients: a pilot/feasibility study. Kalantar-Zadeh K, Braglia A, Chow J, Kwon O, Kuwae N, Colman S, Cockram DB, Kopple JD, J Ren Nutr 2005 15 318 331 10.1016/j.jrn.2005.04.004 16007562 (Pubitemid 40917292)
29. Effect of intradialytic intravenous administration of ω-3 fatty acids on nutritional status and inflammatory response in hemodialysis patients: a pilot study. Szklarek-Kubicka M, Fijałkowska-Morawska J, Zaremba-Drobnik D, Uciński A, Czekalski S, Nowicki M, J Ren Nutr 2009 19 487 493 10.1053/j.jrn.2009.05.007 19616450
30. Essential polyunsaturated fatty acids, inflammation and mortality in dialysis patients. Huang X, Stenvinkel P, Qureshi AR, Risérus U, Cederholm T, Bárány P, Heimbürger O, Lindholm B, Carrero JJ, Nephrol Dial Transplant 2012 27 3615 3620 10.1093/ndt/gfs132 22565059
31. Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. Himmelfarb J, Phinney S, Ikizler TA, Kane J, McMonagle E, Miller G, J Ren Nutr 2007 17 296 304 10.1053/j.jrn.2007.05.011 17720098 (Pubitemid 47284905)
32. Does hepcidin affect erythropoiesis in hemodialysis patients? Eleftheriadis T, Kartsios C, Liakopoulos V, Antoniadi G, Ditsa M, Papadopoulos C, Anifandis G, Skirta A, Markala D, Stefanidis I, Acta Haematol 2006 116 238 244 10.1159/000095873 17119323 (Pubitemid 44795902)
33. Hepcidin is linked to anemia and inflammation in peritoneal dialysis patients. Malyszko J, Malyszko JS, Pawlak K, Drozdowska-Rams L, Brzosko S, Mysliwiec M, Perit Dial Int 2008 28 418 421 18556388
34. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS, et al. Kidney Int 2009 75 976 981 10.1038/ki.2009.21 19212416
35. Effects of omega-3 fatty acid supplementation on lipid levels in endstage renal disease patients. Bowden RG, Jitomir J, Wilson RL, Gentile M, J Ren Nutr 2009 19 259 266 10.1053/j.jrn.2009.01.030 19539180
36. Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients. Kooshki A, Taleban FA, Tabibi H, Hedayati M, Ann Nutr Metab 2011 58 197 202 10.1159/000329727 21757893
37. Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients. Hassan KS, Hassan SK, Hijazi EG, Khazim KO, Ren Fail 2010 32 1031 1035 10.3109/0886022X.2010.510231 20863205
38. Omega-3 fatty acids supplementation does not affect serum lipids in chronic hemodialysis patients. Poulia KA, Panagiotakos DB, Tourlede E, Rezou A, Stamatiadis D, Boletis J, Zampelas A, J Ren Nutr 2011 21 479 484 10.1053/j.jrn.2011.01.018 21439849
39. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T, Blood 2003 101 2461 2463 10.1182/blood-2002-10-3235 12433676 (Pubitemid 36857598)
40. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Kuragano T, Shimonaka Y, Kida A, Furuta M, Nanami M, Otaki Y, Hasuike Y, Nonoguchi H, Nakanishi T, Am J Nephrol 2010 31 534 540 10.1159/000312381 20484891
41. Proinflammatory state, hepcidin, and anemia in older persons. Ferrucci L, Semba RD, Guralnik JM, Ershler WB, Bandinelli S, Patel KV, Sun K, Woodman RC, Andrews NC, Cotter RJ, et al. Blood 2010 115 3810 3816 10.1182/blood-2009-02- 201087 20081092
42. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, Hishida A, Am J Nephrol 2008 28 115 121 10.1159/000109968 17943020 (Pubitemid 350126501)
43. Unexplained aspects of anemia of inflammation. Price EA, Schrier SL, Adv Hematol 2010 2010 1 5
44. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. Ravishankaran P, Karunanithi R, World J Surg Oncol 2011 9 1 6 10.1186/1477-7819-9-1 21214920
45. Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia. Rose WE, Eickhoff JC, Shukla SK, Pantrangi M, Rooijakkers S, Cosgrove SE, Nizet V, Sakoulas G, J Infect Dis 2012 206 1604 1611 10.1093/infdis/jis552 22966128
46. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Locatelli F, Andrulli S, Memoli B, Maffei C, Del Vecchio L, Aterini S, De Simone W, Mandalari A, Brunori G, Amato M, et al. Nephrol Dial Transplant 2006 21 991 998 16384825
47. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Eleftheriadis T, Liakopoulos V, Antoniadi G, Kartsios C, Stefanidis I, Semin Dial 2009 22 70 77 10.1111/j.1525-139X.2008.00532.x 19250447